{'52WeekChange': -0.12892735,
 'SandP52WeekChange': None,
 'address1': 'Building 4',
 'address2': 'Trident Place Mosquito Way',
 'algorithm': None,
 'annualHoldingsTurnover': None,
 'annualReportExpenseRatio': None,
 'ask': 16.05,
 'askSize': 3200,
 'averageDailyVolume10Day': 4598325,
 'averageVolume': 6269490,
 'averageVolume10days': 4598325,
 'beta': 1.537254,
 'beta3Year': None,
 'bid': 15.75,
 'bidSize': 4000,
 'bookValue': 21.787,
 'category': None,
 'circulatingSupply': None,
 'city': 'Hatfield',
 'companyOfficers': [],
 'country': 'United Kingdom',
 'currency': 'USD',
 'dateShortInterest': 1593475200,
 'dayHigh': 16.09,
 'dayLow': 15.76,
 'dividendRate': None,
 'dividendYield': None,
 'earningsQuarterlyGrowth': None,
 'enterpriseToEbitda': 5.952,
 'enterpriseToRevenue': 1.761,
 'enterpriseValue': 20474832896,
 'exDividendDate': 1182902400,
 'exchange': 'NMS',
 'exchangeTimezoneName': 'America/New_York',
 'exchangeTimezoneShortName': 'EDT',
 'expireDate': None,
 'fax': '44 1707 261 803',
 'fiftyDayAverage': 16.440857,
 'fiftyTwoWeekHigh': 23.11,
 'fiftyTwoWeekLow': 12.75,
 'fiveYearAverageReturn': None,
 'fiveYearAvgDividendYield': None,
 'floatShares': 513589500,
 'forwardEps': 4.55,
 'forwardPE': 3.507692,
 'fromCurrency': None,
 'fullTimeEmployees': 35000,
 'fundFamily': None,
 'fundInceptionDate': None,
 'gmtOffSetMilliseconds': '-14400000',
 'headSymbol': None,
 'heldPercentInsiders': 0.01375,
 'heldPercentInstitutions': 0.87962997,
 'industry': 'Drug Manufacturers—Specialty & Generic',
 'isEsgPopulated': True,
 'lastCapGain': None,
 'lastDividendValue': None,
 'lastFiscalYearEnd': 1577750400,
 'lastMarket': None,
 'lastSplitDate': 1065657600,
 'lastSplitFactor': '3:2',
 'legalType': None,
 'logo_url': 'https://logo.clearbit.com/mylan.com',
 'longBusinessSummary': 'Mylan N.V., together with its subsidiaries, develops, '
                        'licenses, manufactures, markets, and distributes '
                        'generic, branded-generic, brand-name, and '
                        'over-the-counter (OTC) pharmaceutical products in '
                        'North America, Europe, and internationally. It offers '
                        'active pharmaceutical ingredients and finished dosage '
                        'forms; and antiretroviral medicines to treat '
                        'HIV/AIDS. The company also provides prescription '
                        'products, such as EpiPen Auto-Injector; Perforomist '
                        'Inhalation Solution; Dymista; Creon; and Influvac, as '
                        'well as YUPELRI, an inhalation solution for the '
                        'maintenance treatment of patients with chronic '
                        'obstructive pulmonary diseases. In addition, it '
                        'markets OTC products, including Cold-EEZE, MidNite, '
                        'Vivarin, Brufen, CB12, and EndWarts. The company '
                        'offers its products to therapeutic areas, such as '
                        'cardiovascular, CNS and anesthesia, dermatology, '
                        'diabetes and metabolism, gastroenterology, '
                        'immunology, infectious disease, oncology, respiratory '
                        "and allergy, and women's health. Its customers "
                        'include retail pharmacies, wholesalers and '
                        'distributors, payers, and insurers and governments, '
                        'as well as institutions, such as hospitals. Mylan '
                        'N.V. has collaboration and license agreements with '
                        'Pfizer Inc.; Momenta Pharmaceuticals, Inc.; '
                        'Theravance Biopharma, Inc.; Biocon Ltd.; Fujifilm '
                        'Kyowa Kirin Biologics Co. Ltd; and Revance '
                        'Therapeutics, Inc. The company was founded in 1961 '
                        'and is based in Hatfield, the United Kingdom.',
 'longName': 'Mylan, Inc.',
 'market': 'us_market',
 'marketCap': 8250474496,
 'maxAge': 1,
 'maxSupply': None,
 'messageBoardId': 'finmb_290203',
 'morningStarOverallRating': None,
 'morningStarRiskRating': None,
 'mostRecentQuarter': 1585612800,
 'navPrice': None,
 'netIncomeToCommon': 62600000,
 'nextFiscalYearEnd': 1640908800,
 'open': 16.02,
 'openInterest': None,
 'payoutRatio': 0,
 'pegRatio': 1.45,
 'phone': '44 1707 853 000',
 'previousClose': 16.08,
 'priceHint': 2,
 'priceToBook': 0.7325469,
 'priceToSalesTrailing12Months': 0.70976704,
 'profitMargins': 0.00538,
 'quoteType': 'EQUITY',
 'regularMarketDayHigh': 16.09,
 'regularMarketDayLow': 15.76,
 'regularMarketOpen': 16.02,
 'regularMarketPreviousClose': 16.08,
 'regularMarketPrice': 16.02,
 'regularMarketVolume': 4103023,
 'revenueQuarterlyGrowth': None,
 'sector': 'Healthcare',
 'sharesOutstanding': 516947008,
 'sharesPercentSharesOut': 0.0633,
 'sharesShort': 32734963,
 'sharesShortPreviousMonthDate': 1590710400,
 'sharesShortPriorMonth': 31484625,
 'shortName': 'Mylan N.V.',
 'shortPercentOfFloat': 0.08140001,
 'shortRatio': 4.85,
 'startDate': None,
 'strikePrice': None,
 'symbol': 'MYL',
 'threeYearAverageReturn': None,
 'totalAssets': None,
 'tradeable': False,
 'trailingAnnualDividendRate': None,
 'trailingAnnualDividendYield': None,
 'trailingEps': 0.12,
 'trailingPE': 133,
 'twoHundredDayAverage': 17.443022,
 'underlyingExchangeSymbol': None,
 'underlyingSymbol': None,
 'uuid': 'af02bec5-077b-3709-98e6-0b880d5cd784',
 'volume': 4103023,
 'volume24Hr': None,
 'volumeAllCurrencies': None,
 'website': 'http://www.mylan.com',
 'yield': None,
 'ytdReturn': None,
 'zip': 'AL10 9UL'}